Home Celladon's Failure Shouldn't Trickle Down To Other Gene Therapy Biotechs
 

Keywords :   


Celladon's Failure Shouldn't Trickle Down To Other Gene Therapy Biotechs

2015-05-27 16:26:47| Biotech - Topix.net

Spark Therapeutics is working on restoring vision for children so they may function properly and meets a big unmet medical need. Bluebird Bio has shown positive preliminary results that are showing to reduce the need for blood transfusions in beta-thalassemia and sickle-cell disease.

Tags: failure therapy gene trickle

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
More »